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Inflammation markers are associated with disease activity in patients with chronic urticaria Sim Da Woon, Yu Ji Eun, and Koh Young-Il; Chonnam National University Medical School, Gwangju, Korea, Republic of (South). RATIONALE: The evaluation of disease activity and severity of chronic idiopathic urticaria (CIU) is essential for the treatment of patients. However, there is no reliable biomarker for such evaluations. Recently, several markers of inflammation have been revealed to be elevated in severe cases of CIU. In this article, we studied the inflammation markers and coagulation markers and their relationship to disease activity in patients with CIU. METHODS: Data on 132 patients with CIU reported in a single tertiary allergy center in Korea during January 2017 to December 2017 were obtained. We collected information regarding various laboratory tests including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), complete blood count (CBC) with differential count, fibrin degradation products (FDP), D-dimer, C3, C4, anti-nuclear antibodies (ANA), antineutrophil cytoplasmic antibody (ANCA) and thyroid function test. We also collected data on age, gender, autologous serum skin test (ASST) and medication score. RESULTS: Eighteen percentages of CIU patients revealed abnormal thyroid-stimulating hormone (TSH) and about one-third of CIU patients had elevated levels of ESR and D-dimer. The levels of CRP in patients with abnormal TSH result were significantly higher than those in patients with normal TSH result (P 5 .001). But no other differences in FDP, D-dimer and ESR were observed among patients with abnormal TSH result. Creactive protein showed correlation with numbers of medication (R 2 50.303, P < .001) but FDP, D-dimer and ESR showed no correlation with numbers of medication. CONCLUSIONS: The measurement of serum CRP may be useful for the assessment of disease activity of CIU. (CSU) is an autoimmune disorder thought to be caused by mast cell activating auto-antibodies to IgE or FcεRI. Standard treatments include second generation antihistamines, omalizumab, and cyclosporine. We present two treatment-refractory CSU patients with elevated D-Dimer, who achieved remission with a low molecular weight heparin (LMWH). METHODS: We reviewed the charts of 2 patients with elevated D-Dimer. RESULTS: Patient A, 67 year old male, presented with urticaria in 2013. Labs were unremarkable excluding elevated D-Dimer (1303ng/mL) and CReactive Protein. Patient was prescribed omalizumab 300mg monthly and updosed to 600 mg. The patient was prescribed 30mg of enoxaparin, an LMWH, daily for 3 weeks following a planned hip replacement. The patient's Urticaria Activity Score (UAS-7) went from 42 to 0 postenoxaparin. However, returned to 42 following the 3 weeks. The patient has resumed enoxaparin 30mg daily for 9 months and still reports a UAS-7 of 0. Patient B, 55 year old male, presented with urticaria in 2016. Labs were unremarkable excluding elevated D-Dimer (6547 ng/mL) and C-Reactive Protein. The patients' UAS-7 was 30. Patient was prescribed omalizumab 300mg, then updosed to 600 mg. Was then prescribed enoxaparin 30mg daily, and their UAS-7 immediately went from 30 to 0, and has remained there for 4 months. CONCLUSIONS: It has been reported that D-Dimer could be a marker of urticaria activity and treatment response. However few patients have ever been treated with LMWH. The coagulation pathway is involved in mast cell degranulation and LMWH may be useful for CSU patients with elevated D-Dimer.
